癌症进展
癌癥進展
암증진전
ONCOLOGY PROGRESS
2014年
4期
403-408
,共6页
二线化疗%老年肿瘤患者%合并症
二線化療%老年腫瘤患者%閤併癥
이선화료%노년종류환자%합병증
second-line chemotherapy%elderly cancer patients%comorbidity
目的：评估不同功能损害的合并症对老年肿瘤患者二线化疗的影响。方法回顾性分析了86例住院接受二线化疗老年肿瘤患者的疗效、生存期和副作用。将患者根据合并症所致功能损害程度分为无合并症（N）、一般合并症（G）和严重合并症（S）三组。结果 N组20例，G组47例，S组19例，三组患者的疾病控制率分别为77.7%、57.5%和42.8%（P>0.1），中位无进展生存期（mPFS）分别为9.8个月、5.1个月和3.7个月（P=0.05），中位总生存期（mOS）分别为23.7个月、13.1个月和10.5个月（P<0.05）。与其他两组相比，S组患者mPFS的下降程度接近统计学意义，mOS的下降程度有统计学意义。N组、G组、S组的3级以上血液学毒性分别为45%、31.9%和36.8%，3级以上非血液学毒性分别为20%、23.4%、42.1%，各组差异无统计学意义。结论大多数伴有不同合并症的老年肿瘤患者可耐受二线化疗，并有不同程度的获益；但应注意调整剂量和控制毒副作用。
目的：評估不同功能損害的閤併癥對老年腫瘤患者二線化療的影響。方法迴顧性分析瞭86例住院接受二線化療老年腫瘤患者的療效、生存期和副作用。將患者根據閤併癥所緻功能損害程度分為無閤併癥（N）、一般閤併癥（G）和嚴重閤併癥（S）三組。結果 N組20例，G組47例，S組19例，三組患者的疾病控製率分彆為77.7%、57.5%和42.8%（P>0.1），中位無進展生存期（mPFS）分彆為9.8箇月、5.1箇月和3.7箇月（P=0.05），中位總生存期（mOS）分彆為23.7箇月、13.1箇月和10.5箇月（P<0.05）。與其他兩組相比，S組患者mPFS的下降程度接近統計學意義，mOS的下降程度有統計學意義。N組、G組、S組的3級以上血液學毒性分彆為45%、31.9%和36.8%，3級以上非血液學毒性分彆為20%、23.4%、42.1%，各組差異無統計學意義。結論大多數伴有不同閤併癥的老年腫瘤患者可耐受二線化療，併有不同程度的穫益；但應註意調整劑量和控製毒副作用。
목적：평고불동공능손해적합병증대노년종류환자이선화료적영향。방법회고성분석료86례주원접수이선화료노년종류환자적료효、생존기화부작용。장환자근거합병증소치공능손해정도분위무합병증（N）、일반합병증（G）화엄중합병증（S）삼조。결과 N조20례，G조47례，S조19례，삼조환자적질병공제솔분별위77.7%、57.5%화42.8%（P>0.1），중위무진전생존기（mPFS）분별위9.8개월、5.1개월화3.7개월（P=0.05），중위총생존기（mOS）분별위23.7개월、13.1개월화10.5개월（P<0.05）。여기타량조상비，S조환자mPFS적하강정도접근통계학의의，mOS적하강정도유통계학의의。N조、G조、S조적3급이상혈액학독성분별위45%、31.9%화36.8%，3급이상비혈액학독성분별위20%、23.4%、42.1%，각조차이무통계학의의。결론대다수반유불동합병증적노년종류환자가내수이선화료，병유불동정도적획익；단응주의조정제량화공제독부작용。
Objective To evaluate the effect of comorbidity in the second line chemotherapy of elderly patients. Method 86 elderly cancer patients treated with the second line chemotherapy from 2010 to 2012 in PUMC Hospi-tal were analyzed retrospectively. The patients were divided into 3 groups according to the vary dysfunction of co-morbidity: no-dysfunction group (N), general dysfunction group (G) and serve dysfunction group (S). Result The disease control rates (DCR) of N group(n =20), G group (n =47) and S group (n =19) were 77.7%, 57.5% and 42.8% (P >0.1), the median progression-free survival (mPFS) were 9.8 months, 5.1 months and 3.7 months (P =0.05), the median overall survival were 23.7 months, 13.1 months and 10.5 months (P <0.05), respectively. The mPFS and mOS of S group were near reaching and reaching statistically significant decline compared with N and G groups. The incidences of hematological and non-hematological toxicity (≥3 grades) were 45% and 20% in N group, 31.9% and 23.4% in G group, 36.8% and 42.1% in S group, respectively. There were no significant differences among the 3 groups. Conclusion Most of elderly cancer patients with comorbidity can be tolerate of the second line chemotherapy and might obtain clinical benefits. But drug dose should be adjusted and adverse effects should be controlled carefully.
